14th DIA Japan Annual Meeting 2017

In drug development, East Asia region, such as Japan, China, Taiwan and Korea, tends to be focused as “Asia” region, however, an environment to conduct multinational clinical trials in ASEAN region has been significantly improved. Indeed, ICH-GCP-complied multinational clinical study results with ASEAN countries have become on public. With this context, in this session, actual practice and situations of clinical study conduct in ASEAN region are to be introduced, and then potential activities in order to further enhance the momentum will be discussed. In order to achieve an ultimate goal, ie. early access to innovative new drug in Asian region, collaboration between East Asia and South East Asia as well as the joint contribution, ie. All Asia, to the drug development will be extensively discussed.